Mining emerging biomedical literature for understanding disease associations in drug discovery.
暂无分享,去创建一个
Johannes M Freudenberg | Deepak K Rajpal | Xiaoyan A Qu | Vinod D Kumar | D. Rajpal | Vinod Kumar | J. Freudenberg | X. Qu | Xiaoyan A. Qu
[1] Samuel Szomstein,et al. Psoriasis Remission after Laparoscopic Roux-En-Y Gastric Bypass for Morbid Obesity , 2004, Obesity surgery.
[2] Steven R Feldman,et al. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. , 2012, Dermatology online journal.
[3] J. Gelfand,et al. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. , 2009, Journal of the American Academy of Dermatology.
[4] E. Christophers,et al. Disease concomitance in psoriasis. , 1995, Journal of the American Academy of Dermatology.
[5] Judith A. Blake,et al. The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse , 2011, Nucleic Acids Res..
[6] M. Fontana,et al. The surgical treatment of metabolic disease and morbid obesity. , 2010, Gastroenterology clinics of North America.
[7] P. Achurra,et al. Psoriasis Following Bariatric Surgery: Clinical Evolution and Impact on Quality of Life on 10 patients , 2012, Obesity Surgery.
[8] P. Sanseau,et al. Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.
[9] Amy E Foxx-Orenstein,et al. Gastrointestinal symptoms and diseases related to obesity: an overview. , 2010, Gastroenterology clinics of North America.
[10] F. Collins,et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.
[11] Frank O. Nestle,et al. Mechanisms of Disease: Psoriasis. , 2009 .
[12] N. Yawalkar,et al. Expression of interleukin-12 is increased in psoriatic skin. , 1998, The Journal of investigative dermatology.
[13] Richard N Bergman,et al. Gastrointestinal hormones and bariatric surgery‐induced weight loss , 2013, Obesity.
[14] Francesco Rubino,et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. , 2010, Annual review of medicine.
[15] Thomas C. Wiegers,et al. Text Mining Effectively Scores and Ranks the Literature for Improving Chemical-Gene-Disease Curation at the Comparative Toxicogenomics Database , 2013, PloS one.
[16] K. Shah,et al. Diagnosis and Treatment of Pediatric Psoriasis: Current and Future , 2013, American Journal of Clinical Dermatology.
[17] Luis Garcia,et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. , 2013, JAMA.
[18] David B. Searls,et al. Can literature analysis identify innovation drivers in drug discovery? , 2009, Nature Reviews Drug Discovery.
[19] Miguel A. Andrade-Navarro,et al. Automatic Annotation for Biological Sequences by Etraction of Keywords from MEDLINE Abstracts: Development of a Prototype System , 1997, ISMB.
[20] Christian Gieger,et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis , 2010, Nature Genetics.
[21] Laura K Ferris,et al. Anti-cytokine therapy in the treatment of psoriasis. , 2013, Cytokine.
[22] Steven R Feldman,et al. Combination therapy for psoriasis in the United States. , 2013, Journal of drugs in dermatology : JDD.
[23] Gregory D. Schuler,et al. Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.
[24] G. Derosa,et al. Anti-obesity drugs: a review about their effects and their safety , 2012, Expert opinion on drug safety.
[25] J. Koo,et al. An evidence-based review of skin cancer rates on biologic therapies , 2012, The Journal of dermatological treatment.
[26] G. Krueger,et al. Psoriasis--recent advances in understanding its pathogenesis and treatment. , 2005, Journal of the American Academy of Dermatology.
[27] Giampiero Girolomoni,et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. , 2008, The American journal of clinical nutrition.
[28] Andrea B Troxel,et al. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. , 2012, Archives of dermatology.
[29] Mayte Suárez-Fariñas,et al. Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis , 2012, The Journal of investigative dermatology.
[30] R. Leibel,et al. Molecular physiology of weight regulation in mice and humans , 2008, International Journal of Obesity.
[31] André Reis,et al. Identification of low-frequency TRAF3IP2 coding variants in psoriatic arthritis patients and functional characterization , 2012, Arthritis Research & Therapy.
[32] James T. Elder,et al. Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics shows locus heterogeneity at PSORS1. , 2010, Tissue antigens.
[33] S. Waldman,et al. Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy , 2010, Clinical pharmacology and therapeutics.
[34] Carlo Tomino,et al. Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis , 2008, Dermatology.
[35] Supriyo De,et al. Systematic analysis, comparison, and integration of disease based human genetic association data and mouse genetic phenotypic information , 2010, BMC Medical Genomics.
[36] Suyan Tian,et al. Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease , 2012, PloS one.
[37] William H. Majoros,et al. Genomics and natural language processing , 2002, Nature Reviews Genetics.
[38] Eric W Hossler,et al. Gastric bypass surgery improves psoriasis. , 2011, Journal of the American Academy of Dermatology.
[39] C. Fiehn,et al. Methotrexate transport mechanisms: the basis for targeted drug delivery and ß-folate-receptor-specific treatment. , 2010, Clinical and experimental rheumatology.
[40] R W Groves,et al. Detection of circulating adhesion molecules in erythrodermic skin disease. , 1995, Journal of the American Academy of Dermatology.
[41] David Carling,et al. AMPK, insulin resistance, and the metabolic syndrome. , 2013, The Journal of clinical investigation.
[42] Alan Menter,et al. Psoriasis and the metabolic syndrome. , 2008, Journal of drugs in dermatology : JDD.
[43] Scott A Waldman,et al. New advances in models and strategies for developing anti-obesity drugs , 2013, Expert opinion on drug discovery.
[44] T. Jenssen,et al. A literature network of human genes for high-throughput analysis of gene expression , 2001 .
[45] Padmini Srinivasan,et al. Distilling Conceptual Connections from MeSH Co-Occurrences , 2004, MedInfo.
[46] Jennifer E Towne,et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. , 2013, The Journal of investigative dermatology.
[47] F. Anania,et al. The Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism , 2013, Seminars in Liver Disease.
[48] Christopher R. Lindholm,et al. A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats , 2012, Journal of Physiology and Biochemistry.
[49] S. Piaserico,et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study , 2007, The British journal of dermatology.
[50] Luis Puig,et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.
[51] Daniel Hanisch,et al. Playing Biology's Name Game: Identifying Protein Names in Scientific Text , 2002, Pacific Symposium on Biocomputing.
[52] J. Prins,et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. , 1997, Journal of immunology.
[53] Michal Magid-Slav,et al. Gastrointestinal weight-loss surgery: glimpses at the molecular level. , 2013, Drug discovery today.
[54] Giampiero Girolomoni,et al. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. , 2005, European journal of dermatology : EJD.
[55] Barend Mons,et al. In silico discovery and experimental validation of new protein–protein interactions , 2011, Proteomics.
[56] Donny Wong,et al. The pharmaceutical market for obesity therapies , 2012, Nature Reviews Drug Discovery.
[57] J. Gelfand,et al. Is there truly a risk of lymphoma from biologic therapies? , 2009, Dermatologic therapy.
[58] P. O’Brien,et al. Bariatric surgery: Mechanisms, indications and outcomes , 2010, Journal of gastroenterology and hepatology.
[59] Michael Hinckley,et al. Impact of obesity and smoking on psoriasis presentation and management. , 2005, Archives of dermatology.
[60] Barend Mons,et al. Generic Information Can Retrieve Known Biological Associations: Implications for Biomedical Knowledge Discovery , 2013, PloS one.
[61] Carsten Carlberg,et al. Current status of vitamin D signaling and its therapeutic applications. , 2012, Current topics in medicinal chemistry.
[62] James T. Elder,et al. Genetic associations of psoriasis in a Pakistani population , 2013, The British journal of dermatology.
[63] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[64] Norbert Reider,et al. A marriage of two “Methusalem” drugs for the treatment of psoriasis? , 2013, Dermato-endocrinology.
[65] Zhen Hu,et al. BMC Bioinformatics BioMed Central Methodology article CLEAN: CLustering Enrichment ANalysis , 2009 .
[66] J. Gudjonsson,et al. Analysis of global gene expression and genetic variation in psoriasis. , 2007, Journal of the American Academy of Dermatology.
[67] David J Margolis,et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. , 2004, The journal of investigative dermatology. Symposium proceedings.
[68] Honghui Zhou,et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab , 2011, Nature Biotechnology.
[69] L. Skov,et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti‐inflammatory drugs: a Danish real‐world cohort study , 2013, Journal of internal medicine.
[70] Hagit Shatkay,et al. Genes, Themes, and Microarrays: Using Information Retrieval for Large-Scale Gene Analysis , 2000, ISMB.
[71] Joyce A. Mitchell,et al. Gene Indexing: Characterization and Analysis of NLM's GeneRIFs , 2003, AMIA.
[72] Philippe Sanseau,et al. The role of translational bioinformatics in drug discovery. , 2011, Drug discovery today.
[73] E. Finkelstein,et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. , 2009, Health affairs.
[74] Pál Pacher,et al. Modulating the endocannabinoid system in human health and disease – successes and failures , 2013, The FEBS journal.
[75] David B. Searls,et al. Literature mining in support of drug discovery , 2008, Briefings Bioinform..
[76] Hong Liang Tey,et al. Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents , 2013, BioDrugs.
[77] L. Kaplan,et al. Pharmacologic therapies for obesity. , 2010, Gastroenterology clinics of North America.
[78] David J. Margolis,et al. Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom , 2011, The Journal of investigative dermatology.
[79] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[80] P. O'Neil,et al. Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study , 2012, Obesity.